<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36148821</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>16</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-1331</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month></PubDate></JournalIssue><Title>European journal of neurology</Title><ISOAbbreviation>Eur J Neurol</ISOAbbreviation></Journal><ArticleTitle>Effect of RNS60 in amyotrophic lateral sclerosis: a phase II multicentre, randomized, double-blind, placebo-controlled trial.</ArticleTitle><Pagination><StartPage>69</StartPage><EndPage>86</EndPage><MedlinePgn>69-86</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/ene.15573</ELocationID><Abstract><AbstractText Label="BACKGROUND AND PURPOSE">Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with limited treatment options. RNS60 is an immunomodulatory and neuroprotective investigational product that has shown efficacy in animal models of ALS and other neurodegenerative diseases. Its administration has been safe and well tolerated in ALS subjects in previous early phase trials.</AbstractText><AbstractText Label="METHODS">This was a phase II, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial. Participants diagnosed with definite, probable or probable laboratory-supported ALS were assigned to receive RNS60 or placebo administered for 24&#x2009;weeks intravenously (375&#x2009;ml) once a week and via nebulization (4 ml/day) on non-infusion days, followed by an additional 24&#x2009;weeks off-treatment. The primary objective was to measure the effects of RNS60 treatment on selected biomarkers of inflammation and neurodegeneration in peripheral blood. Secondary objectives were to measure the effect of RNS60 on functional impairment (ALS Functional Rating Scale-Revised), a measure of self-sufficiency, respiratory function (forced vital capacity, FVC), quality of life (ALS Assessment Questionnaire-40, ALSAQ-40) and survival. Tolerability and safety were assessed.</AbstractText><AbstractText Label="RESULTS">Seventy-four participants were assigned to RNS60 and 73 to placebo. Assessed biomarkers did not differ between arms. The mean rate of decline in FVC and the eating and drinking domain of ALSAQ-40 was slower in the RNS60 arm (FVC, difference 0.41 per week, standard error 0.16, p =&#x2009;0.0101; ALSAQ-40, difference -0.19 per week, standard error 0.10, p =&#x2009;0.0319). Adverse events were similar in the two arms. In a post hoc analysis, neurofilament light chain increased over time in bulbar onset placebo participants whilst remaining stable in those treated with RNS60.</AbstractText><AbstractText Label="CONCLUSIONS">The positive effects of RNS60 on selected measures of respiratory and bulbar function warrant further investigation.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. European Journal of Neurology published by John Wiley &amp; Sons Ltd on behalf of European Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Beghi</LastName><ForeName>Ettore</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-2542-0469</Identifier><AffiliationInfo><Affiliation>Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pupillo</LastName><ForeName>Elisabetta</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-4420-8076</Identifier><AffiliationInfo><Affiliation>Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bianchi</LastName><ForeName>Elisa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonetto</LastName><ForeName>Valentina</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0003-0456-2054</Identifier><AffiliationInfo><Affiliation>Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luotti</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pasetto</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bendotti</LastName><ForeName>Caterina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tortarolo</LastName><ForeName>Massimo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sironi</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Camporeale</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sherman</LastName><ForeName>Alexander V</ForeName><Initials>AV</Initials><AffiliationInfo><Affiliation>Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paganoni</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Sean M. Healey and AMG Center for ALS at Mass General Hospital, Department of Neurology, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Spaulding Rehabilitation Hospital, Department of PM&amp;R, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scognamiglio</LastName><ForeName>Ada</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>ALS Expert Center 'Maggiore della Carit&#xe0;' Hospital and University of Piemonte Orientale, Novara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Marchi</LastName><ForeName>Fabiola</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-0197-1880</Identifier><AffiliationInfo><Affiliation>ALS Expert Center 'Maggiore della Carit&#xe0;' Hospital and University of Piemonte Orientale, Novara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bongioanni</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Spinal Cord Injuries Section, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Del Carratore</LastName><ForeName>Renata</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-7504-0379</Identifier><AffiliationInfo><Affiliation>Institute of Clinical Physiology, CNR-, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caponnetto</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>IRCCS Ospedale Policlinico San Martino, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diamanti</LastName><ForeName>Luca</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-4540-6886</Identifier><AffiliationInfo><Affiliation>IRCCS Mondino Foundation, Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinelli</LastName><ForeName>Daniele</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>IRCCS Mondino Foundation, Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calvo</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-5122-7243</Identifier><AffiliationInfo><Affiliation>Centro Regionale Esperto per la Sclerosi Laterale Amiotrofica, Dipartimento di Neuroscienze 'Rita Levi Montalcini', Universit&#xe0; degli Studi di Torino, AOU Citt&#xe0; della Salute e della Scienza di Torino, Torino, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Filosto</LastName><ForeName>Massimiliano</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-2852-7512</Identifier><AffiliationInfo><Affiliation>Department of Clinical and Experimental Sciences, University of Brescia, Gussago Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Padovani</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Clinical and Experimental Sciences, University of Brescia, Gussago Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piccinelli</LastName><ForeName>Stefano Cotti</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Department of Clinical and Experimental Sciences, University of Brescia, Gussago Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ricci</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medical, Surgical and Neurological Sciences, University of Siena, Siena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dalla Giacoma</LastName><ForeName>Stefania</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medical, Surgical and Neurological Sciences, University of Siena, Siena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Angelis</LastName><ForeName>Nicoletta</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Medical, Surgical and Neurological Sciences, University of Siena, Siena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Inghilleri</LastName><ForeName>Maurizio</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Universit&#xe0; di Roma 'Sapienza' UOSD Malattie Neurodegenerative, Centro Malattie Rare Neuromuscolari Policlinico Universitario Umberto I, Roma, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spataro</LastName><ForeName>Rossella</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-8910-3131</Identifier><AffiliationInfo><Affiliation>ALS Clinical Research Center, AOUP 'P Giaccone' - University of Palermo, Palermo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>La Bella</LastName><ForeName>Vincenzo</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0003-2045-1864</Identifier><AffiliationInfo><Affiliation>ALS Clinical Research Center, AOUP 'P Giaccone' - University of Palermo, Palermo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Logroscino</LastName><ForeName>Giancarlo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Center for neurodegenerative diseases and the Aging Brain, Department of Clinical Research in Neurology of the University of Bari at 'Pia Fondazione Card G. Panico 'Hospital Tricase, Tricase, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Basic Medicine Neuroscience and Sense Organs, University Aldo Moro Bari, Bari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lunetta</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Centro Clinico NeMO Milano, Fondazione Serena ONLUS, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tarlarini</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Centro Clinico NeMO Milano, Fondazione Serena ONLUS, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mandrioli</LastName><ForeName>Jessica</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, Azienda Ospedaliero-Universitaria Di Modena, Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinelli</LastName><ForeName>Ilaria</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0003-2566-3671</Identifier><AffiliationInfo><Affiliation>Department of Neurosciences, Azienda Ospedaliero-Universitaria Di Modena, Modena, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simonini</LastName><ForeName>Cecilia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Azienda Ospedaliero-Universitaria Di Modena, Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zucchi</LastName><ForeName>Elisabetta</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Azienda Ospedaliero-Universitaria Di Modena, Modena, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience PhD Program, University of Modena and Reggio Emilia, Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monsurr&#xf2;</LastName><ForeName>Maria Rosaria</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Advanced Medical and Surgical Sciences, University of Campania 'Luigi Vanvitelli', Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ricciardi</LastName><ForeName>Dario</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-4862-4165</Identifier><AffiliationInfo><Affiliation>Department of Advanced Medical and Surgical Sciences, University of Campania 'Luigi Vanvitelli', Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trojsi</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Advanced Medical and Surgical Sciences, University of Campania 'Luigi Vanvitelli', Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riva</LastName><ForeName>Nilo</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-0513-9517</Identifier><AffiliationInfo><Affiliation>Neurology Unit, Neurorehabilitation Unit, and Neurophysiology Unit, Vita-Salute San Raffaele University and San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Filippi</LastName><ForeName>Massimo</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-5485-0479</Identifier><AffiliationInfo><Affiliation>Neurology Unit, Neurorehabilitation Unit, and Neurophysiology Unit, Vita-Salute San Raffaele University and San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simone</LastName><ForeName>Isabella Laura</ForeName><Initials>IL</Initials><Identifier Source="ORCID">0000-0002-7429-3091</Identifier><AffiliationInfo><Affiliation>Neurology Unit, Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari, Bari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sorar&#xf9;</LastName><ForeName>Gianni</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-9691-6328</Identifier><AffiliationInfo><Affiliation>Motor Neuton Disease Center, Department of Neurosciences, Azienda Ospedale Universit&#xe0; di Padova, Padova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spera</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Azienda Ospedaliera 'S Maria' Terni, Terni, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Florio</LastName><ForeName>Lucia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Neurology Department, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Messina</LastName><ForeName>Sonia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Russo</LastName><ForeName>Massimo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siciliano</LastName><ForeName>Gabriele</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of clinical and experimental medicine, University of Pisa, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conte</LastName><ForeName>Amelia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centro Clinico NEMO-Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saddi</LastName><ForeName>Maria Valeria</ForeName><Initials>MV</Initials><AffiliationInfo><Affiliation>Neurology Department, San Francesco Hospital, Nuoro, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carboni</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Neurology Department, San Francesco Hospital, Nuoro, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mazzini</LastName><ForeName>Letizia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>ALS Expert Center 'Maggiore della Carit&#xe0;' Hospital and University of Piemonte Orientale, Novara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>RNS60-ALS Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Neurol</MedlineTA><NlmUniqueID>9506311</NlmUniqueID><ISSNLinking>1351-5101</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000627108">RNS60</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">clinical trial</Keyword><Keyword MajorTopicYN="N">placebo-controlled</Keyword><Keyword MajorTopicYN="N">randomized</Keyword><Keyword MajorTopicYN="N">treatment</Keyword></KeywordList><CoiStatement>E. Beghi reports grants from the Italian Ministry of Health, grants from SOBI, personal fees from Arvelle Therapeutics, outside the submitted work. E. Beghi reports grants from American ALS Association for the conduct of the present study. E. Pupillo reports grants from the Italian Ministry of Health, grants from AIFA, outside the submitted work. A. Sherman reports research grants from the ALS Association, ALS Finding a Cure and the NIH, outside the submitted work. S. Paganoni reports research grants from Amylyx Therapeutics, Revalesio Corporation, UCB/Ra Pharma, Biohaven, Clene, Prilenia, Seelos, the ALS Association, the American Academy of Neurology, ALS Finding a Cure, the Salah Foundation, the Spastic Paraplegia Foundation, the Muscular Dystrophy Association and reports personal consulting fees for advisory panels from Orion and Cytokinetics. All of them are outside the submitted work. M. Filosto reports serving on a scientific advisory board for Amicus, Sanofi, Sarepta; honoraria for speaking engagements for Sanofi, Alnylam. All of them are outside the submitted work. A. Padovani serves on a scientific advisory board: Director of School of Neurology, University of Brescia; President&#x2010;elect of the National Society of Neurology SIN; GE Healthcare, Lilly and Actelion Ltd Pharmaceuticals. Travel funded by a commercial entity: Roche, Ely&#x2010;Lilly, Biogen, Zambon, Nutricia, Lundbeck. Serving as a journal editor, associate editor, or on an editorial advisory board: MDPI. Patents held or pending: Method of generation of a diagnostic index for Alzheimer's disease, electronic device for implementing the method and system, 2016. Honoraria for speaking engagements: He has received honoraria from Nutricia, PIAM, Langstone Technology, GE Healthcare, Lilly and Chiesi. Commercial research support: Advisory and served on the Scientific Advisory Board for GE Healthcare, Lilly and Actelion Ltd Pharmaceuticals. Government research support (including funding organization, grant number, and role): He has participated as PI in more than 30 research projects funded by the Ministry of Health and MIUR. Support from a non&#x2010;profit foundation or society: CHDI Foundation, Fondazione Cariplo. All of them are outside the submitted work. G. Logroscino received funds from Roche, Amplifon; he received travel funds for participation in a congress as speaker. All of them are outside the submitted work. C. Lunetta received compensation for consulting services from Neuraltus, Cytokinetics, Mitsubishi Tanabe Pharma Europe and Italfarmaco and has received funds from ARISLA and Italian Ministry of Health. All of them are outside the submitted work. J. Mandrioli received research grants from Fondazione Italiana di Ricerca per la Sclerosi Laterale Amiotrofica (ARISLA), the Agenzia Italiana del Farmaco (AIFA), the Italian Ministry of Health, Emilia Romagna Regional Health Authority, Roche, Pfizer. All of them are outside the submitted work. F. Trojsi served as a journal editor, associate editor, or on an editorial advisory board: Associate Editor of <i>Frontiers in Neuroscience/Frontiers in Neurology</i> (section Neurodegeneration) (2017&#x2013;today) and <i>Orphanet Journal of Rare Diseases</i> (BMC/ Springer Nature) (2021); Academic Editor of <i>Brain Sciences</i> (MDPI Ed.) (2021). Fee for consultant: Alnylam Italy Srl (2020). All of them are outside the submitted work. All other authors report no disclosures.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Enia</LastName><ForeName>Gabriele</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zucchella</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pinzani</LastName><ForeName>Lorenzo</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Giorgi</LastName><ForeName>Lorena</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nicoletti</LastName><ForeName>Celeste</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Semprucci</LastName><ForeName>Elisa</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davide Arippol</LastName><ForeName>Emilio</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Giussani</LastName><ForeName>Giorgia</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Graziani</LastName><ForeName>Monica</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferrari</LastName><ForeName>Cinzia</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cantello</LastName><ForeName>Roberto</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bersano</LastName><ForeName>Enrica</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dolciotti</LastName><ForeName>Cristina</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Masciandaro</LastName><ForeName>Silvia Maria</ForeName><Initials>SM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Da Prato</LastName><ForeName>Ilaria</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cabona</LastName><ForeName>Corrado</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meo</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ceroni</LastName><ForeName>Mauro</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dal Fabbro</LastName><ForeName>Beatrice</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chi&#xf2;</LastName><ForeName>Adriano</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moglia</LastName><ForeName>Cristina</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Manera</LastName><ForeName>Umberto</ForeName><Initials>U</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fuda</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Casale</LastName><ForeName>Federico</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Marco</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salamone</LastName><ForeName>Paolina</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Giannini</LastName><ForeName>Fabio</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bocci</LastName><ForeName>Silvia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ceccanti</LastName><ForeName>Marco</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cambieri</LastName><ForeName>Chiara</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Libonati</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moret</LastName><ForeName>Federica</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frasca</LastName><ForeName>Vittorio</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coletti</LastName><ForeName>Tiziana</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tortelli</LastName><ForeName>Rosanna</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Capozzo</LastName><ForeName>Rosa</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gerardi</LastName><ForeName>Francesca</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sansone</LastName><ForeName>Valeria</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fini</LastName><ForeName>Nicola</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gianferrari</LastName><ForeName>Giulia</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gessani</LastName><ForeName>Annalisa</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Falzone</LastName><ForeName>Yuri</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schito</LastName><ForeName>Paride</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pozzi</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Domi</LastName><ForeName>Teuta</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>D'Errico</LastName><ForeName>Eustachio</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morea</LastName><ForeName>Antonella</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Milella</LastName><ForeName>Gianmarco</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gizzi</LastName><ForeName>Matteo</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paci</LastName><ForeName>Francesca</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferracchiato</LastName><ForeName>Simonetta</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zarrelli</LastName><ForeName>Michele</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Desina</LastName><ForeName>Nino</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Govoni</LastName><ForeName>Alessandra</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schirinzi</LastName><ForeName>Erika</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simoncini</LastName><ForeName>Costanza</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sabatelli</LastName><ForeName>Mario</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bernardo</LastName><ForeName>Daniela</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bisogni</LastName><ForeName>Giulia</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Piras</LastName><ForeName>Giovanna</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Monne</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Manca</LastName><ForeName>Elisabetta</ForeName><Initials>E</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>9</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>23</Day><Hour>5</Hour><Minute>54</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36148821</ArticleId><ArticleId IdType="pmc">PMC10092300</ArticleId><ArticleId IdType="doi">10.1111/ene.15573</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Beghi E, Mennini T, Bendotti C, et al. The heterogeneity of amyotrophic lateral sclerosis: a possible explanation of treatment failure. Curr Med Chem. 2007;14(30):3185&#x2010;3200.</Citation><ArticleIdList><ArticleId IdType="pubmed">18220753</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2012. Mar 14;2012(3):CD001447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7055506</ArticleId><ArticleId IdType="pubmed">22419278</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing Group; Edaravone (MCI&#x2010;186) ALS 19 Study Group . Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double&#x2010;blind, placebo&#x2010;controlled trial. Lancet Neurol. 2017;16(7):505&#x2010;512.</Citation><ArticleIdList><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>De Marchi F, Munitic I, Amedei A, et al. Interplay between immunity and amyotrophic lateral sclerosis: clinical impact. Neurosci Biobehav Rev 2021;127:958&#x2010;978. doi: 10.1016/j.neubiorev.2021.06.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neubiorev.2021.06.027</ArticleId><ArticleId IdType="pmc">PMC8428677</ArticleId><ArticleId IdType="pubmed">34153344</ArticleId></ArticleIdList></Reference><Reference><Citation>Cali&#xf3; ML, Henriques E, Siena A, Bertoncini CRA, Gil&#x2010;Mohapel J, Rosenstock TR. Mitochondrial dysfunction, neurogenesis, and epigenetics: putative implications for amyotrophic lateral sclerosis neurodegeneration and treatment. Front Neurosci. 2020;14:679. doi:10.3389/fnins.2020.00679</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2020.00679</ArticleId><ArticleId IdType="pmc">PMC7373761</ArticleId><ArticleId IdType="pubmed">32760239</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta AR, Walters R, Waldron FM, et al. Targeting mitochondrial dysfunction in amyotrophic lateral sclerosis: a systematic review and meta&#x2010;analysis. Brain Commun. 2019;1(1):fcz009.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7056361</ArticleId><ArticleId IdType="pubmed">32133457</ArticleId></ArticleIdList></Reference><Reference><Citation>Granatiero V, Manfredi G. Mitochondrial transport and turnover in the pathogenesis of amyotrophic lateral sclerosis. Biology. 2019;8(2):36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6627920</ArticleId><ArticleId IdType="pubmed">31083575</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallarola A, Sironi F, Tortarolo M, et al. RNS60 exerts therapeutic effects in the SOD1 ALS mouse model through protective glia and peripheral nerve rescue. J Neuroinflammation. 2018;15(1):65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5833072</ArticleId><ArticleId IdType="pubmed">29495962</ArticleId></ArticleIdList></Reference><Reference><Citation>Khasnavis S, Roy A, Ghosh S, Watson R, Pahan K. Protection of dopaminergic neurons in a mouse model of Parkinson's disease by a physically&#x2010;modified saline containing charge&#x2010;stabilized nanobubbles. J Neuroimmune Pharmacol. 2014;9(2):218&#x2010;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">24122363</ArticleId></ArticleIdList></Reference><Reference><Citation>Rangasamy SB, Ghosh S, Pahan K. RNS60, a physically&#x2010;modified saline, inhibits glial activation, suppresses neuronal apoptosis and protects memory in a mouse model of traumatic brain injury. Exp Neurol. 2020;328:113279.</Citation><ArticleIdList><ArticleId IdType="pubmed">32151546</ArticleId></ArticleIdList></Reference><Reference><Citation>Mondal S, Rangasamy SB, Ghosh S, Watson RL, Pahan K. Nebulization of RNS60, a physically&#x2010;modified saline, attenuates the adoptive transfer of experimental allergic encephalomyelitis in mice: implications for multiple sclerosis therapy. Neurochem Res. 2017;42(5):1555&#x2010;1570.</Citation><ArticleIdList><ArticleId IdType="pubmed">28271325</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao VT, Khan D, Jones RG, et al. Potential benefit of the charge&#x2010;stabilized nanostructure saline RNS60 for myelin maintenance and repair. Sci Rep. 2016;6:30020. doi:10.1038/srep30020</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep30020</ArticleId><ArticleId IdType="pmc">PMC4958964</ArticleId><ArticleId IdType="pubmed">27451946</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandra G, Kundu M, Rangasamy SB, et al. Increase in mitochondrial biogenesis in neuronal cells by RNS60, a physically&#x2010;modified saline, via phosphatidylinositol 3&#x2010;kinase&#x2010;mediated upregulation of PGC1&#x3b1;. J Neuroimmune Pharmacol. 2018;13(2):143&#x2010;162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5928179</ArticleId><ArticleId IdType="pubmed">29188424</ArticleId></ArticleIdList></Reference><Reference><Citation>Modi KK, Jana A, Ghosh S, Watson R, Pahan K. A physically&#x2010;modified saline suppresses neuronal apoptosis, attenuates tau phosphorylation and protects memory in an animal model of Alzheimer's disease. PLoS One. 2014;9(8):e103606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4121132</ArticleId><ArticleId IdType="pubmed">25089827</ArticleId></ArticleIdList></Reference><Reference><Citation>Mondal S, Martinson JA, Ghosh S, Watson R, Pahan K. Protection of Tregs, suppression of Th1 and Th17 cells, and amelioration of experimental allergic encephalomyelitis by a physically&#x2010;modified saline. PLoS One. 2012;7(12):e51869.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3527485</ArticleId><ArticleId IdType="pubmed">23284794</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivannikov MV, Sugimori M, Llin&#xe1;s RR. Neuromuscular transmission and muscle fatigue changes by nanostructured oxygen. Muscle Nerve. 2017;55(4):555&#x2010;563.</Citation><ArticleIdList><ArticleId IdType="pubmed">27422738</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Alshikho MJ, Luppino S, et al. A pilot trial of RNS60 in amyotrophic lateral sclerosis. Muscle Nerve. 2019;59(3):303&#x2010;308.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6379136</ArticleId><ArticleId IdType="pubmed">30458059</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasetto L, Grassano M, Pozzi S, et al. Defective cyclophilin A induces TDP&#x2010;43 proteinopathy: implications for amyotrophic lateral sclerosis and frontotemporal dementia. Brain. 2021;144(12):3710&#x2010;3726.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8719849</ArticleId><ArticleId IdType="pubmed">34972208</ArticleId></ArticleIdList></Reference><Reference><Citation>
Trolese M C, Scarpa C, Melfi V, et al. Boosting the peripheral immune response in the skeletal muscles improved motor function in ALS transgenic mice. Mol Ther
2022;30(8):2760&#x2010;2784. doi:10.1016/j.ymthe.2022.04.018
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2022.04.018</ArticleId><ArticleId IdType="pmc">PMC9372324</ArticleId><ArticleId IdType="pubmed">35477657</ArticleId></ArticleIdList></Reference><Reference><Citation>Zucchi E, Bonetto V, Sorar&#xf9; G, et al. Neurofilaments in motor neuron disorders: towards promising diagnostic and prognostic biomarkers. Mol Neurodegener. 2020;15(1):58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7559190</ArticleId><ArticleId IdType="pubmed">33059698</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron Diseases . El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1(5):293&#x2010;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamidou B, Marin B, Lautrette G, et al. Exploring the diagnosis delay and ALS functional impairment at diagnosis as relevant criteria for clinical trial enrolment. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(7&#x2010;8):519&#x2010;527.</Citation><ArticleIdList><ArticleId IdType="pubmed">28762856</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura F, Fujimura C, Ishida S, et al. Progression rate of ALSFRS&#x2010;R at time of diagnosis predicts survival time in ALS. Neurology. 2006;66(2):265&#x2010;267.</Citation><ArticleIdList><ArticleId IdType="pubmed">16434671</ArticleId></ArticleIdList></Reference><Reference><Citation>Rentzos M, Rombos A, Nikolaou C, et al. Interleukin&#x2010;17 and interleukin&#x2010;23 are elevated in serum and cerebrospinal fluid of patients with ALS: a reflection of Th17 cells activation? Acta Neurol Scand. 2010;122(6):425&#x2010;429.</Citation><ArticleIdList><ArticleId IdType="pubmed">20219021</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel JS, Beers DR, Wen S, et al. Regulatory T&#x2010;lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol Med. 2013;5(1):64&#x2010;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3569654</ArticleId><ArticleId IdType="pubmed">23143995</ArticleId></ArticleIdList></Reference><Reference><Citation>Casoni F, Basso M, Massignan T, et al. Protein nitration in a mouse model of familial amyotrophic lateral sclerosis: possible multifunctional role in the pathogenesis. J Biol Chem. 2005;280(16):16295&#x2010;16304.</Citation><ArticleIdList><ArticleId IdType="pubmed">15699043</ArticleId></ArticleIdList></Reference><Reference><Citation>Nardo G, Pozzi S, Mantovani S, et al. Nitroproteomics of peripheral blood mononuclear cells from patients and a rat model of ALS. Antioxid Redox Signal. 2009;11(7):1559&#x2010;1567.</Citation><ArticleIdList><ArticleId IdType="pubmed">19290778</ArticleId></ArticleIdList></Reference><Reference><Citation>Nardo G, Pozzi S, Pignataro M, et al. Amyotrophic lateral sclerosis multiprotein biomarkers in peripheral blood mononuclear cells. PLoS One. 2011;6(10):e25545.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3187793</ArticleId><ArticleId IdType="pubmed">21998667</ArticleId></ArticleIdList></Reference><Reference><Citation>Filareti M, Luotti S, Pasetto L, et al. Decreased levels of foldase and chaperone proteins are associated with an early&#x2010;onset amyotrophic lateral sclerosis. Front Mol Neurosci. 2017;10:99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5382314</ArticleId><ArticleId IdType="pubmed">28428745</ArticleId></ArticleIdList></Reference><Reference><Citation>Luotti S, Pasetto L, Porcu L, et al. Diagnostic and prognostic values of PBMC proteins in amyotrophic lateral sclerosis. Neurobiol Dis. 2020;139:104815.</Citation><ArticleIdList><ArticleId IdType="pubmed">32087285</ArticleId></ArticleIdList></Reference><Reference><Citation>Baron P, Bussini S, Cardin V, et al. Production of monocyte chemoattractant protein&#x2010;1 in amyotrophic lateral sclerosis. Muscle Nerve. 2005;32(4):541&#x2010;544.</Citation><ArticleIdList><ArticleId IdType="pubmed">15962273</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo J, Yang X, Gao L, Zang D. Evaluating the levels of CSF and serum factors in ALS. Brain Behav. 2017;7(3):e00637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5346523</ArticleId><ArticleId IdType="pubmed">28293476</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhle J, Lindberg RL, Regeniter A, et al. Increased levels of inflammatory chemokines in amyotrophic lateral sclerosis. European J Neurol. 2009;16(6):771&#x2010;774.</Citation><ArticleIdList><ArticleId IdType="pubmed">19236470</ArticleId></ArticleIdList></Reference><Reference><Citation>Tateishi T, Yamasaki R, Tanaka M, et al. CSF chemokine alterations related to the clinical course of amyotrophic lateral sclerosis. J Neuroimmunol. 2010;222(1&#x2010;2):76&#x2010;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">20381883</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Zhang L, Wang L, et al. Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. Neurology. 2020;95(1):e59&#x2010;e69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7371380</ArticleId><ArticleId IdType="pubmed">32385188</ArticleId></ArticleIdList></Reference><Reference><Citation>Palma E, Reyes&#x2010;Ruiz JM, Lopergolo D, et al. Acetylcholine receptors from human muscle as pharmacological targets for ALS therapy. Proc Natl Acad Sci U S A. 2016;113(11):3060&#x2010;3065.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4801305</ArticleId><ArticleId IdType="pubmed">26929355</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T, Cudkowicz M, Shaw PJ, et al. Phase 1&#x2013;2 trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med. 2020;383(2):109&#x2010;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T, Cudkowicz M. In American Neurological Association Annual Meeting (Virtual, 2021 Oct 17&#x2013;19).</Citation></Reference><Reference><Citation>Benatar M, Wuu J, Andersen PM, et al. Design of a randomized, placebo&#x2010;controlled, phase 3 trial of tofersen initiated in clinically presymptomatic SOD1 variant carriers: the ATLAS Study. Neurotherapeutics. 2022. doi:10.1007/s13311-022-01237-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-022-01237-4</ArticleId><ArticleId IdType="pmc">PMC9587202</ArticleId><ArticleId IdType="pubmed">35585374</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph AC, Dorst J, Dreyhaupt J, et al. Effect of high&#x2010;caloric nutrition on survival in amyotrophic lateral sclerosis. Ann Neurol. 2020;87(2):206&#x2010;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">31849093</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>